Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment.

[1]  M. Woodward,et al.  C-reactive Protein, Idiopathic Venous Thromboembolism and Hormone Replacement Therapy , 2000, Thrombosis and Haemostasis.

[2]  E. Giltay,et al.  Oral Ethinyl Estradiol, but not Transdermal 17β-estradiol, Increases Plasma C-reactive Protein Levels in Men , 2000, Thrombosis and Haemostasis.

[3]  J. Schenker,et al.  Women's reproductive health: monotheistic religious perspectives , 2000, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[4]  C. Stehouwer,et al.  Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[5]  A. Döring,et al.  Oral contraceptive use is associated with a systemic acute phase response , 1999 .

[6]  C. Kluft.  EditorialPro-inflammatory effect of oestrogens , 1999 .

[7]  J. Manson,et al.  Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.

[8]  E. Barrett-Connor,et al.  Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.

[9]  C. Stehouwer,et al.  Increased C-reactive Protein Levels during Short-term Hormone Replacement Therapy in Healthy Postmenopausal Women , 1999, Thrombosis and Haemostasis.

[10]  F. Rosendaal,et al.  Increased Levels of Factor VIII and Fibrinogen in Patients with Venous Thrombosis Are not Caused by Acute Phase Reactions , 1999, Thrombosis and Haemostasis.

[11]  G. Ciliberto,et al.  Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. , 1998, Circulation.

[12]  C. Kluft,et al.  C-reactive protein: a cardiovascular risk factor report on the CRP hot-topic workshop October 1, 1997 , 1998 .

[13]  D. Petitti.  Hormone replacement therapy and heart disease prevention: experimentation trumps observation. , 1998, JAMA.

[14]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[15]  J. Douketis,et al.  A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. , 1997, Archives of internal medicine.

[16]  H. Eichler,et al.  Menstrual cycle-associated changes in blood levels of interleukin-6, alpha1 acid glycoprotein, and C-reactive protein. , 1997, The Journal of laboratory and clinical medicine.

[17]  T. Meade,et al.  Hormone Replacement Therapy and Haemostatic Function , 1997, Thrombosis and Haemostasis.

[18]  J. Vandenbroucke,et al.  Oral Contraceptives and Thrombotic Disease: Risk of Venous Thromboembolism , 1997, Thrombosis and Haemostasis.

[19]  M. Lansink,et al.  Effect of Oral Contraceptives on Haemostasis Variables , 1997, Thrombosis and Haemostasis.

[20]  P. Meijer,et al.  Serum neopterin in acute coronary syndromes , 1997, The Lancet.

[21]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[22]  H. Hemker,et al.  Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second‐ and third‐generation oral contraceptives , 1997, British journal of haematology.

[23]  J. Castellsagué,et al.  Hormone replacement therapy and risk of venous thromboembolism: population based case-control study , 1997, BMJ.

[24]  W. Duyvenvoorde,et al.  Effect of 17β-Estradiol on Plasma Lipids and LDL Oxidation in Postmenopausal Women With Type II Diabetes Mellitus , 1997 .

[25]  C. Kluft,et al.  Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[26]  J. Vandenbroucke,et al.  Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis , 1995, The Lancet.

[27]  C. Ternisien,et al.  Interleukin‐10 and pentoxifylline inhibit C‐reactive protein‐induced tissue factor gene expression in peripheral human blood monocytes , 1994, FEBS letters.

[28]  P. Reitsma,et al.  Factor VII and Fibrinogen Levels as Risk Factors for Venous Thrombosis , 1994, Thrombosis and Haemostasis.

[29]  J. Gauldie,et al.  The acute phase response. , 1994, Immunology today.

[30]  A. Whitehead,et al.  The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. , 1994, Immunology today.

[31]  G. Vercellotti,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor , 1993 .

[32]  E. Ernst.  Oral contraceptives, fibrinogen and cardiovascular risk. , 1992, Atherosclerosis.

[33]  I. Kushner,et al.  The Acute Phase Response Is Mediated by Heterogeneous Mechanisms a , 1989, Annals of the New York Academy of Sciences.

[34]  C. Prowse,et al.  Room Temperature, Microtray Chromogenic Assay of Factor VIII:C , 1986, Vox sanguinis.

[35]  J. Amiral,et al.  Application of enzyme immunoassays to coagulation testing. , 1984, Clinical chemistry.

[36]  J. Sternberg.  A rate nephelometer for measuring specific proteins by immunoprecipitin reactions. , 1977, Clinical chemistry.

[37]  A. Clauss,et al.  Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens , 1957 .

[38]  H. Hall,et al.  Comparison of the effects of a contraceptive patch and oral contraceptives on coagulation parameters , 2000 .

[39]  M. Laffan,et al.  Elevation of FVIII: C in Venous Thromboembolism Is Persistent and Independent of the Acute Phase Response , 2000, Thrombosis and Haemostasis.

[40]  S. Freedman,et al.  Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. , 2000, Circulation.

[41]  P. Meijer,et al.  SERUM NEOPTERIN IN ACUTE CORONARY SYNDROMES. AUTHORS' REPLY , 1997 .

[42]  M. Frölich,et al.  Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM , 1997, Diabetologia.

[43]  J. Vandenbroucke.  Epidemiology … Annotation of Esbjerg I Consensus meeting , 1996 .